---
title: "Relay Therapeutics to report Q2 results after markets close"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294409309.md"
description: "Relay Therapeutics will release its second-quarter 2026 financial results and provide a corporate update on August 6, 2026, following the close of U.S. markets."
datetime: "2026-07-30T20:12:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294409309.md)
  - [en](https://longbridge.com/en/news/294409309.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294409309.md)
generator: "portal-rs"
---

# Relay Therapeutics to report Q2 results after markets close

-   Relay Therapeutics schedules second-quarter 2026 results release, corporate update for Aug. 6, 2026, following the U.S. market close. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607301605PRIMZONEFULLFEED9801177) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [RLAY.US](https://longbridge.com/en/quote/RLAY.US.md)

## Related News & Research

- [Sherwin-Williams announces Q3 2026 dividend of R$ 0.28 per unit](https://longbridge.com/en/news/299050724.md)
- [ADM announces Q3 2026 dividend of R$ 0.22 per unit](https://longbridge.com/en/news/298917252.md)
- [Prudential Financial announces R$ 2.41 per unit dividend for Q3 2026 BDRs](https://longbridge.com/en/news/298940810.md)
- [Lineage declares Q3 2026 cash dividend of $0.53 per share](https://longbridge.com/en/news/299091753.md)
- [Invitation Homes announces Q3 2026 dividend of R$ 0.21 per unit](https://longbridge.com/en/news/299044268.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**